DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1098 Hoffbrand AV, Herbert V. Nutritional anemias. Semin Hematol,
1999, 36:13–23.
Hoffman HN 2nd, Phyliky RL, Fleming CR. Zinc-induced copper
deficiency. Gastroenterology, 1988, 94:508–512.
Huang E, Nocka K, Beier DR, et al. The hematopoietic growth
factor KL is encoded by the Sl locus and is the ligand of the
c-kit receptor, the gene product of the W locus. Cell, 1990,
63:225–233.
Hubel K, Carter RA, Liles WC, et al. Granulocyte transfusion
therapy for infections in candidates and recipients of HPC
transplantation: A comparative analysis of feasibility and outcome
for community donors versus related donors.
Transfusion, 2002, 42:1414–1421.
Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin
(Epo) in view of the pharmacokinetics of the
recombinant drugs rhEpo and NESP. Eur J Haematol, 2002,
69:265–274.
Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate
reduces epoetin requirements in hemodialysis patients with
elevated ferritin. J Am Soc Nephrol, 2008, 19:372–379.
Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared
with intravenous epoetin in patients receiving hemodialysis.
Department of Veterans Affairs Cooperative Study Group on
Erythropoietin in Hemodialysis Patients. N Engl J Med, 1998,
339:578–583.
Kaushansky K. Thrombopoietin. N Engl J Med, 1998,
339:746–754.
Kawasaki ES, Ladner MB, Wang AM, et al. Molecular cloning of
a complementary DNA encoding human macrophage-specific
colony-stimulating factor (CSF-1). Science, 1985, 230:291–296.
Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition,
distribution and regulation. Nat Chem Biol, 2008,
4:176–185.
Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim
in patients with chronic immune thrombocytopenic purpura: A
double-blind randomised controlled trial. Lancet, 2008,
371:395–403.
Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy
increases platelet yields in healthy platelet donors. Blood,
2001, 98:1339–1345.
Lalioti V, Muruais G, Tsuchiya Y, et al. Molecular mechanisms
of copper homeostasis. Front Biosci, 2009, 14:4878–4903.
Laurell CB. What is the function of transferrin in plasma? Blood,
1951, 6:183–187.
Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the
development of antibodies to thrombopoietin. Blood, 2001,
98:3241–3248.
Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor
and granulocyte-macrophage colony-stimulating factor (2).
N Engl J Med, 1992, 327:99–106.
Linz R, Lutsenko S. Copper-transporting ATPases ATP7A and
ATP7B: cousins, not twins. J Bioenerg Biomembr, 2007,
39:403–407.
Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin
alfa on hematologic parameters and quality of life in cancer
patients receiving nonplatinum chemotherapy: Results of a
randomized, double-blind, placebo-controlled trial. J Clin
Oncol, 2001, 19:2865–2874.
Lok S, Kaushansky K, Holly RD, et al. Cloning and expression
of murine thrombopoietin cDNA and stimulation of platelet
production in vivo. Nature, 1994, 369:565–568.
SECTION IV
INFLAMMATION. IMMUNOMODULATION, AND HEMATOPOIESIS
Macdougall IC. Pure red cell aplasia with anti-erythropoietin
antibodies occurs more commonly with one formulation of
epoetin alfa than another. Curr Med Res Opin, 2004, 20:
83–86.
Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-hIF-1 system.
A key mediator of oxygen homeostasis. Adv Exp Med Biol,
2001, 502:365–376.
McLean E, Cogswell M, Egli I, et al. Worldwide prevalence
of anaemia, WHO Vitamin and Mineral Nutrition
Information System, 1993–2005. Public Health Nutr, 2009,
12:444–454.
Monsen ER, Hallberg L, Layrisse M, et al. Estimation of available
dietary iron. Am J Clin Nutr, 1978, 31:134–141.
Moskowitz CH, Stiff P, Gordon MS, et al. Recombinant
methionyl human stem cell factor and filgrastim for peripheral
blood progenitor cell mobilization and transplantation in
non-Hodgkin’s lymphoma patients—results of a phase I/II
trial. Blood, 1997, 89:3136–3147.
MRC Vitamin Study Research Group. Prevention of neural tube
defects: Results of the Medical Research Council Vitamin
Study. Lancet, 1991, 338:131–137.
Nakorn,TN, Miyamoto T, Weissman IL. Characterization of
mouse clonogenic megakaryocyte progenitors. Proc Natl Acad
Sci U S A, 2003, 100:205–210.
Neben TY, Loebelenz J, Hayes L, et al. Recombinant human
interleukin-11 stimulates megakaryocytopoiesis and increases
peripheral platelets in normal and splenectomized mice. Blood,
1993, 81:901–908.
Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia
of inflammation by inducing the synthesis of the iron
regulatory hormone hepcidin. J Clin Invest, 2004, 113:
1271–1276.
Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant
human granulocyte-macrophage colony-stimulating factor
in graft failure after bone marrow transplantation. Blood,
1990, 76:245–253.
Owen WF Jr. Optimizing the use of parenteral iron in end-stage
renal disease patients: Focus on issues of infection and cardiovascular
disease. Introduction. Am J Kidney Dis, 1999,
34:S1–2.
Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary
antimicrobial peptide synthesized in the liver. J Biol Chem,
2001, 276:7806–7810.
Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations
in the HIF2A gene associated with erythrocytosis. Blood,
2008, 111:5400–5402.
Reynolds EH. Mental effects of anticonvulsants and folic acid
metabolism. Brain, 1968, 91:197–214.
Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in
patients with cancer: Evidence-based clinical practice guidelines
of the American Society of Clinical Oncology and the
American Society of Hematology. Blood, 2002, 100:
2303–2320.
Robinson AR, Mladenovic J. Lack of clinical utility of folate levels
in the evaluation of macrocytosis or anemia. Am J Med,
2001, 110:88–90.
Scott JM, Weir DG. Drug-induced megaloblastic change. Clin
Haematol, 1980, 9:587–606.
Sengolge G, Horl WH, Sunder-Plassmann G. Intravenous iron
therapy: Well-tolerated, yet not harmless. Eur J Clin Invest,
2005, 35 (suppl 3):46–51.